Celltrion

First Mover and Now Europe’s Largest mAb Biosimilar Portfolio¹

Our 12 EMA Approved Products For Hospital Pharmacists

Built on Trust, Toward Innovation.

Some of the products might not be marketed in your country. Check with your health authorities the availability of the products in your country.

ES–26-00003 Febrero 2026

References

EMA Medicines Data. Available at: https://www.ema.europa.eu/en/medicines/download-medicine-data (Last access: February 2026)
Remsima™ SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026)
Kim NH, Lee JH, Hong SN, Yoon H, Kang HW, Lee SH, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2019 Sep;34(9):1523-1532. doi:10.1111/jgh.14645.
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, et al. Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 4;19(6):jjaf060. doi:10.1093/ecco-jcc/jjaf060.
Schreiber S, Colombel JF, Hanauer SB, Sandborn WJ, Danese S, Lee SJ, et al. Comparing outcomes with subcutaneous infliximab (CT-P13 SC) by baseline immunosuppressant use: a post hoc analysis of the LIBERTY-CD and LIBERTY-UC studies. Inflamm Bowel Dis. 2025 Oct;31(10):2714-2724. Published 2025 Apr 30. doi:10.1093/ibd/izaf038.
Avtozma™ SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026)
Tyenne® SmPC EMA, Fresenius Kabi Deutschland GmbH (last access February 2026).;
Roactemra® SmPC EMA, Roche Registration GmbH (last access February 2026).
SteQeyma™ SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026)
Yuflyma™ SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026);
Humira® SmPC EMA, Abbvie Deutschland Gmbh & Co. Kg
Coghlan J, He H, Schwendeman AS. Overview of Humira® biosimilars: current European landscape and future implications. J Pharm Sci. 2021 Apr;110(4):1572-1582. doi:10.1016/j.xphs.2021.02.003.
Omlyclo™ SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026)
Xolair® SmPC EMA, Novartis Europharm Limited . (last access February 2026);
Bishton M, Marshall S, Harchowal J, Salles G, Golfier C, Tucci A, et al. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin’s lymphoma or chronic lymphocytic leukemia: a retrospective non-interventional post-authorization safety study in Europe. Hematol Oncol. 2022 Aug;40(3):370-380. doi:10.1002/hon.2978. PMID:35168291
Truxima™ SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026);
Mabthera® SmPC EMA, Roche Registration Gmbh (last access February 2026);
Rixathon® SmPC EMA, Sandoz Gmbh, (last access February 2026);
Ruxience® SmPC EMA, Pfizer Europe Ma Eeig (last access February 2026);
Ituxredi® SmPC EMA, Reddy Holding Gmbh (last access February 2026);
Herzuma™ SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026);
Herceptin® SmPC EMA, Roche Registration GmbH (last access February 2026).
Kanjinti® SmPC EMA, Amgen Europe B.V. (last access February 2026).
Trazimera® SmPC EMA, Pfizer Europe MA EEIG (last access February 2026).
Ogivri® SmPC EMA, Biosimilar Collaborations Ireland Limited (last access February 2026).
Herwenda® SmPC EMA, Sandoz GmbH (last access February 2026).
Dazublys® SmPC EMA, CuraTeQ Biologics s.r.o (last access February 2026).
Ontruzant® SmPC EMA, Samsung Bioepis NL B.V. (last access February 2026).

Zercepac® SmPC EMA, Accord Healthcare S.L.U. (last access February 2026).
Stebbing J, Baranau Y, Baryash V, Moiseyenko V, Boliukh D, Antone N, et al. Six-year survival outcomes for patients with HER2-positive early breast cancer treated with CT-P6 or reference trastuzumab: observational follow-up study of a phase 3 randomised controlled trial. BioDrugs. 2023 May;37(3):433-440. doi:10.1007/s40259-023-00582-w.
IQVIA MIDAS Quartery Audit from MAT Q3/2023 to MAT Q3/2025
Vegzelma^TM SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026);
Avastin® SmPC EMA, Roche Registration Gmbh (last access February 2026);
Zirabev® SmPC EMA, Pfizer Europe Ma Eeig (last access February 2026);
Abevmy® SmPC EMA, Biosimilar Collaborations Ireland Limited (last access February 2026);
Aybintio® SmPC EMA, Samsung Bioepis Nl B.V. (last access February 2026);
Mvasi® SmPC EMA, Amgen Technology (Ireland) Unlimited Company (last access February 2026);
Alymsys® SmPC EMA, Mabxience Research S.L. (last access February 2026);
Oyavas® SmPC EMA, Stada Arzneimittel Ag (last access February 2026);
Onbevzi® SmPC EMA, Samsung Bioepis NL B.V. Medicinal product no longer authorised. (last access February 2026);
Avzivi® SmPC EMA, FGK Representative Service GmbH (last access February 2026);
Verschraegen C, Andric ZG, et al. 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer. Ann Oncol. 2022 Sep;33(Suppl 7):S1024-S1025. doi:10.1016/j.annonc.2022.07.1153
Eydenzelt^TM SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026);
Yesafil® SmPC EMA, Biosimilar Collaborations Ireland Limited. (last access February 2026);
Opuviz® SmPC EMA, Samsung Bioepis NL B.V. (last access February 2026);
Ahzantive/Baiama® SmPC EMA, Formycon AG (last access February 2026);
Pavblu® SmPC EMA, Amgen Technology (Ireland) UC, (last access February 2026);
Afqlir/Enzeevu® SmPC EMA, Sandoz GmbH (last access February 2026);
Afiveg® SmPC EMA, STADA Arzneimittel AG (last access February 2026);
Vgenfli® SmPC EMA, Zakłady Farmaceutyczne POLPHARMA S.A. (last access February 2026);
Eyluxvi® SmPC EMA, Biolitec Pharma Limited Zweigniederlassung Jena (last access February 2026);
Terumo Corporation, Terumo Pharmaceutical Solutions offers pre-fillable syringe solutions for demanding low dose applications such as ophthalmic. Available at https://www.terumomedical.com/news-and-events/news/terumo-offers-prefillable-syringe-solutions.html. Accessed January 2025
Stoboclo^TM SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026);
Prolia® SmPC EMA, Amgen Europe B.V. (last access February 2026);
Jubbonti® SmPC EMA, Sandoz Gmbh (last access February 2026);
Obodence® SmPC EMA, Samsung Bioepis Nl B.V. (last access February 2026);
Conexxence® SmPC EMA, Fresenius Kabi Deutschland GmbH (last access February 2026);
Osenvelt^TM SmPC EMA, Celltrion Healthcare Hungary Kft. (last access February 2026);
Xgeva® SmPC EMA, Amgen Europe B.V. (last access February 2026);
Wyost® SmPC EMA, Sandoz Gmbh (last access February 2026);
Xbryk® SmPC EMA, Samsung Bioepis Nl B.V. (last access February 2026);
Bomyntra® SmPC EMA, Fresenius Kabi Deutschland GmbH (last access February 2026);
Junod® SmPC EMA, Gedeon Richter Plc. (last access February 2026);

Built on Trust, Toward Innovation.

References

Technical specifications